Northwest Biotherapeutics (NWBO) EPS (Basic) Growth (3y) (2013 - 2026)
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 86.03% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.21% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.73% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -38.31% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.51% |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | 92.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 92.45% |
| Mar 31, 2026 | 94.07% |
| Dec 31, 2025 | 26.64% |
| Sep 30, 2025 | -722.65% |
| Jun 30, 2025 | -621.14% |
| Mar 31, 2025 | -860.59% |
| Dec 31, 2024 | -28.30% |
| Sep 30, 2024 | -1,355.05% |
| Jun 30, 2024 | -69.99% |
| Mar 31, 2024 | -47.62% |
| Dec 31, 2023 | 67.89% |
| Sep 30, 2023 | -333.82% |
| Jun 30, 2023 | -445.42% |
| Mar 31, 2023 | -1,202.56% |
| Dec 31, 2022 | -65.74% |
| Sep 30, 2022 | -42.53% |
| Jun 30, 2022 | -321.39% |
| Mar 31, 2022 | 25.65% |
| Dec 31, 2021 | 161.80% |
| Sep 30, 2021 | -34.87% |